Acquired hemophilia A: a review of recent data and new therapeutic options

Massimo Franchini, Stefania Vaglio, Giuseppe Marano, Carlo Mengoli, Sara Gentili, Simonetta Pupella, Giancarlo Maria Liumbruno

Research output: Contribution to journalArticlepeer-review


Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. Methods: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. Results: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. Conclusion: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.

Original languageEnglish
Pages (from-to)514-520
Number of pages7
Issue number9
Publication statusPublished - Oct 21 2017


  • Acquired hemophilia A
  • bleeding
  • eradication therapy
  • factor VIII

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Acquired hemophilia A: a review of recent data and new therapeutic options'. Together they form a unique fingerprint.

Cite this